Showing session: reset
Precision Medicine Clinical Trials
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
- Free
- slides video
- audio + slides
- All slides included
Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Discussant
Alex A. Adjei
Mayo Clinic, Rochester, MN, United States
- Free
- audio + slides
- Some slides withheld
European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
Birgit Geoerger
Inst. Gustave Roussy, Villejuif, France
- Free
- slides video
- audio + slides
- All slides included
Discussant
Yael P Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
- Free
- audio + slides
- Some slides withheld
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Silvia Marsoni
Grande Ospedale Metropolitano Niguarda, Milano, Italy
- Free
- slides video
- audio + slides
- All slides included
Discussant
Rodrigo Dienstmann
Vall d´Hebron Inst. of Oncology, Barcelona, Spain